12:00 AM
 | 
Sep 03, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Kalydeco ivacaftor regulatory update

FDA issued a notice about the potential for cataract development in children receiving cystic fibrosis (CF) drug Kalydeco ivacaftor from Vertex based on the results of an animal study. The agency said cataracts were seen in juvenile rats treated with Kalydeco from postnatal days...

Read the full 200 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >